Amylyx Pharmaceuticals, Inc. Earnings Per Share (Diluted)
Amylyx Pharmaceuticals, Inc. (AMLX) reported Earnings Per Share (Diluted) of -$0.39 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.39.
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.37.
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.30.
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.37.
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2025 was -$1.53.
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2024 was -$4.43, a 732.86% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2023 was $0.70.
- Amylyx Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2022 was -$3.39.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.39 10-Q · filed 2026-08-06 | -$0.76 10-Q · filed 2026-08-06 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.37 10-Q · filed 2026-05-07 | -$0.67 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.04 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.66 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.53 10-K · filed 2026-03-03 |
| 2025-09-30 | -$0.37 10-Q · filed 2025-11-06 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.25 10-Q · filed 2025-11-06 | -$1.77 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.46 10-Q · filed 2026-08-06 | -$0.88 10-Q · filed 2026-08-06 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.42 10-Q · filed 2026-05-07 | -$0.95 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.97 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.01 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.61 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$2.68 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$4.43 10-K · filed 2026-03-03 |
| 2024-09-30 | -$1.07 10-Q · filed 2025-11-06 | -$2.14 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$3.89 10-Q · filed 2025-11-06 | -$3.79 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-06-30 | -$1.07 10-Q · filed 2025-08-07 | -$2.82 10-Q · filed 2025-08-07 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-03-31 | -$1.75 10-Q · filed 2025-05-08 | -$1.66 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.35 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2023-12-31 | $0.07 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.37 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.68 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.70 10-K · filed 2025-03-04 |
| 2023-09-30 | $0.30 10-Q · filed 2024-11-07 | $0.61 derived: net income ÷ weighted average shares · filed 2024-11-07 | $0.63 10-Q · filed 2024-11-07 | $0.03 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2023-06-30 | $0.31 10-Q · filed 2024-08-08 | $0.34 10-Q · filed 2024-08-08 | -$0.28 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.10 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2023-03-31 | $0.02 10-Q · filed 2024-05-09 | -$0.60 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.46 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.35 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2022-12-31 | -$0.65 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$1.56 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$2.48 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$3.39 10-K · filed 2024-02-22 |
| 2022-09-30 | -$0.92 10-Q · filed 2023-11-09 | -$1.85 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.77 10-Q · filed 2023-11-09 | -$4.20 derived: net income ÷ weighted average shares · filed 2024-02-22 |
| 2022-06-30 | -$0.93 10-Q · filed 2023-08-10 | -$1.85 10-Q · filed 2023-08-10 | -$3.35 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$4.97 derived: net income ÷ weighted average shares · filed 2024-02-22 |
| 2022-03-31 | -$0.93 10-Q · filed 2023-05-11 | -$2.60 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$4.57 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$6.76 derived: net income ÷ weighted average shares · filed 2024-02-22 |
| 2021-12-31 | -$4.10 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$7.53 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$10.95 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$13.35 10-K · filed 2024-02-22 |
| 2021-09-30 | -$3.42 10-Q · filed 2022-11-10 | -$6.83 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$9.20 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$3.41 10-Q · filed 2022-08-11 | -$5.75 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |